DOCSLIB.ORG

(12) STANDARD PATENT (11) Application No. AU 2012204162 B2 (19) AUSTRALIAN PATENT OFFICE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) STANDARD PATENT (11) Application No. AU 2012204162 B2 (19) AUSTRALIAN PATENT OFFICE (12) STANDARD PATENT (11) Application No. AU 2012204162 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title Chemosensory receptor ligand-based therapies (51) International Patent Classification(s) A61K 31/4709 (2006.01) A61P 3/00 (2006.01) A61K 31/155 (2006.01) A61P 3/04 (2006.01) A61K 31/194 (2006.01) A61P 3/10 (2006.01) A61K 31/198 (2006.01) A61P 7/12 (2006.01) A61K 31/20 (2006.01) A61P 19/10 (2006.01) A61K 31/201 (2006.01) A61P 21/00 (2006.01) A61K 31/353 (2006.01) A61P 25/00 (2006.01) A61K 31/575 (2006.01) A61P 25/22 (2006.01) A61K 31/7016 (2006.01) A61P 25/24 (2006.01) A61K 31/7032 (2006.01) A61P 37/00 (2006.01) A61K 31/704 (2006.01) C12N 5/07 (2010.01) A61P 1/00 (2006.01) (21) Application No: 2012204162 (22) Date of Filing: 2012.01.06 (87) WIPO No: W012/094636 (30) Priority Data (31) Number (32) Date (33) Country 61/430,914 2011.01.07 US (43) Publication Date: 2012.07.12 (44) Accepted Journal Date: 2017.04.20 (71) Applicant(s) Elcelyx Therapeutics, Inc. (72) Inventor(s) Baron, Alain D.;Brown, Martin R.;Jones, Christopher R. G.;Beeley, Nigel R. A.;Fineman, Mark S. (74) Agent / Attorney Spruson & Ferguson, L 35 St Martins Tower 31 Market St, Sydney, NSW, 2000, AU (56) Related Art WO 2007/007189 A2 US 2010/0331419 Al WO 2006/086727 A2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2012/094636 A3 12 July 2012 (12.07.2012) W I PO I P CT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, C12N5/07(2010.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, GT, HN, (21) International Application Number: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, PCT/US2012/020548 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 6 January 2012 (06.01.2012) OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (25) Filing Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated,for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/430,914 7 January 2011 (07.01.2011) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, (71) Applicant (for all designated States except US): TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, ELCELYX THERAPEUTICS, INC. [US/US]; 11995 El DK, EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Camino Real, Suite 305, San Diego, CA 92130 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors; and SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (75) Inventors/Applicants (for US only): BARON, Alain D. GW, ML, MR, NE, SN, TD, TG). [US/US]; 12863 Baywind Point, San Diego, CA 92130 Declarations under Rule 4.17: (US). BROWN, Martin R. [US/US]; 834 Tolita Avenue, - as to applicant's entitlement to applyfor and be granted a Coronado, CA 92118 (US). JONES, Christopher R. G. patent (Rule 4.17(ii)) [US/US]; 13713 Freeport Road, San Diego, CA 92129 (US). BEELEY, Nigel R. A. [US/US]; 227 Loma Corta Published: Drive, Solana Beach, CA 92075 (US). FINEMAN, Mark - with internationalsearch report (Art. 21(3) S. [US/US]; 12444 Oakfort Place, San Diego, CA 92130 (US). - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (74) Agent: LORENZ, Todd A.; Arnold & Porter LLP, Three amendments (Rule 48.2(h)) Embarcadero Center, 7th Floor, San Francisco. CA 94111 (US). (88) Date of publication of the international search report: 4 October 2012 (81) Designated States (unless otherwise indicated,for every kind of national protection available): AE, AG, AL, AM, (54) Title: CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES (57) Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, f4 obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter recept or ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. WO 2012/094636 PCT/US2012/020548 CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES CROSS-REFERENCE [0001] This application claims the benefit of U.S. Provisional Application No. 61/430,914, filed January 7, 2011, which is incorporated herein by reference. BACKGROUND OF THE INVENTION [0002] Despite the longstanding, massive, effort to develop effective treatments for diabetes, metabolic syndrome, obesity, overweight and related metabolic conditions, the number of people worldwide who suffer from them is rapidly growing. These conditions result in numerous medical complications, a lowered quality of life, shortened lifespan, lost work productivity, a strain on medical systems, and a burden on medical insurance providers that translates into increased costs for all. Additionally, maintenance of health, including healthy body weight and healthy blood glucose levels is desirable. [0003] Type II diabetes treatments in use or development are designed to lower blood glucose levels. They include mimetics of GLP-1 (glucagon-like peptide-1), a hormone that plays a key role in regulating insulin, glucose and hunger. Examples of mimetics are the GLP-1 receptor agonist, Exenatide (Byetta@) and the GLP-1 analog Liraglutide. Other drugs inhibit DPP-IV, an enzyme that rapidly degrades endogenous GLP-1. Exenatide is a GLP- 1 receptor agonist that is degraded more slowly by DPP-IV. Liraglutide, a GLP-1 analog, is attached to a fatty acid molecule that binds to albumin and slows the rate of GLP-1 release and its degradation. (See, e.g., Nicolucci, et al., 2008, "Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes," Acta Biomedica 79(3):184-91 and U.S. Pat. No. 5,424,286 "Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same.") [0004] Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type II diabetes by lowering both basal and post-prandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. However, metformin is reported to be substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. For example, in patients with known or suspected impaired renal function such as those with advanced age, metformin administration requires close dose monitoring and titration to prevent lactic acidosis, a potentially fatal metabolic complication. Patients with concomitant -1- WO 2012/094636 PCT/US2012/020548 cardiovascular or liver disease, sepsis, and hypoxia have also increased the risk of lactic acidosis. Thus, metformin remains an unavailable and/or risky treatment for certain patient groups due to its side effects. [0005] Until very recently, obesity treatments include two FDA-approved drugs. Orlistat (Xenical@) reduces intestinal fat absorption by inhibiting pancreatic lipase. Sibutramine (Meridia@), taken off the market in Europe and the USA, decreases appetite by inhibiting deactivation of the neurotransmitters norepinephrine, serotonin, and dopamine. Undesirable side-effects, including effects on blood pressure, have been reported with these drugs. (See, e.g., "Prescription Medications for the Treatment of Obesity," NIH Publication No. 07-4191, December 2007). Surgical treatments, including gastric bypass surgery and gastric banding, are available, but only in extreme cases. These procedures can be dangerous, and furthermore may not be appropriate options for patients with more modest weight loss goals. Enteroendocrine Cells and Chemosensory Receptor Ligands [0006] Certain intestinal cells, L cells, have been reported to produce GLP-1 in response to glucose, fat and amino acid stimulation. These and other such "enteroendocrine cells" also reportedly produce other hormones involved in processes relating to glucose and fuel metabolism, including oxyntomodulin, reported to ameliorate glucose intolerance and suppress appetite, PYY (peptide YY), also observed to suppress appetite, CCK (cholecystokinin), which reportedly stimulates the digestion of fat and protein and also reduces food intake, GLP-2, which reportedly induces gut cell proliferation, and GIP (gastric inhibitory polypeptide, also called glucose-dependent insulinotropic peptide), an incretin secreted from the intestinal K cells that has been observed to augment glucose-dependent insulin secretion. (See, e.g., Jang, et al., 2007, "Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1," PNAS 104(38):15069-74 and Parlevliet, et al., 2007, "Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet," Am J Physiol Endocrinol Metab 294(1):E142-7). Guanylin and uroguanylin are peptides of 15- and 16-amino acids in length, respectively, that are reportedly secreted by intestinal epithelial cells as prohormones and require enzymatic conversion into active hormones. Recently, it has been reported that uroguanylin may have a satiety-inducing function.
Load more

Recommended publications
  • Morpho-Anatomical Study of Stevia Rebaudiana Roots Grown in Vitro and in Vivo
    Revista Brasileira de Farmacognosia 27 (2017) 34–39 ww w.elsevier.com/locate/bjp Original Article Morpho-anatomical study of Stevia rebaudiana roots grown in vitro and in vivo a a a b c Rafael V. Reis , Talita P.C. Chierrito , Thaila F.O. Silva , Adriana L.M. Albiero , Luiz A. Souza , d a,b a,b,∗ José E. Gonc¸ alves , Arildo J.B. Oliveira , Regina A.C. Gonc¸ alves a Programa de Pós-graduac¸ ão em Ciências Farmacêuticas, Universidade Estadual de Maringá, Maringá, PR, Brazil b Departamento de Farmácia, Universidade Estadual de Maringá, Campus Universitário, Maringá, PR, Brazil c Departamento de Biologia, Universidade Estadual de Maringá, Campus Universitário, Maringá, PR, Brazil d Programa de Mestrado em Promoc¸ ão da Saúde, Centro Universitário de Maringá, Maringá, PR, Brazil a r a b s t r a c t t i c l e i n f o Article history: Stevia rebaudiana (Bertoni) Bertoni, Asteraceae, is used as a food additive because its leaves are a source Received 16 May 2016 of steviol glycosides. There are examples of tissue culture based on micropropagation and phytochemical Accepted 14 August 2016 production of S. rebaudiana leaves but there are few studies on adventitious root culture of S. rebaudiana. Available online 7 October 2016 More than 90% of the plants used in industry are harvested indiscriminately. In order to overcome this situation, the development of methodologies that employ biotechnology, such as root culture, provides Keywords: suitable alternatives for the sustainable use of plants. The aim of this study was to compare morpho- Stevia rebaudiana anatomical transverse sections of S.
    [Show full text]
  • Nutritional and Medicinal Properties of Stevia Rebaudiana
    Review Article Curr Res Diabetes Obes J Volume 13 Issue 4 - July 2020 Copyright © All rights are reserved by Fasiha Ahsan DOI: 10.19080/CRDOJ.2020.13.555867 Nutritional and Medicinal Properties of Stevia Rebaudiana Fasiha Ahsan*, Shahid Bashir and Faiz-ul-Hassan Shah University Institute of Diet and Nutritional Sciences, The University of Lahore, Pakistan Submission: June 25, 2020; Published: July 16, 2020 *Corresponding author: Fasiha Ahsan, PhD Scholar, University Institute of Diet and Nutritional Sciences, The University of Lahore, Pakistan Abstract Researches on new molecules with the least toxic effects and better potency is on its way and more attention is being given upon medicinal plants for forcing away the above problems. Medicinal plants have been recognized as potential drug candidates. Stevia, a natural sweetener with medicinal properties and also having nutritional, therapeutic and industrial importance is being used all over the world. Stevia rebaudiana leaves are usually referred to as candy, sweet and honey leaves. Diterpene glycosides are responsible for its high sweetening potential of leaves. The phytochemical properties of bioactive chemicals present in stevia leaves are involves in maintaining the physiological functions of human body. Paper also highlights the importance of nutritional aspects of dried stevia leaves, metabolism of stevia, effects of it consumption on human health and clinical studies related to stevia ingestion. Various medicinal properties of stevia leaves discussed in paper like anti-hyperglycemia, anti-oxidative, hypotensive, nephro-protective, hepato protective, antibacterial and antifungal. Basic purpose of this review to understand the medicinalKeywords: potential Stevia; Diabetes;of stevia and Phytochemicals; its acceptance Medicinal as a significant plant; Steviol;raw material Nutrition; for human Disorders diet.
    [Show full text]
  • Steviol Glycosides from Stevia Rebaudiana Bertoni
    0 out of 21 Residue Monograph prepared by the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 84th meeting 2017 Steviol Glycosides from Stevia rebaudiana Bertoni This monograph was also published in: Compendium of Food Additive Specifications. Joint FAO/WHO Expert Committee on Food Additives (JECFA), 84th meeting 2017. FAO JECFA Monographs 20 © FAO/WHO 2017 1 out of 21 STEVIOL GLYCOSIDES FROM STEVIA REBAUDIANA BERTONI Prepared at the 84th JECFA (2017) and published in FAO JECFA Monographs 20 (2017), superseding tentative specifications prepared at the 82nd JECFA (2016) and published in FAO JECFA Monographs 19 (2016). An ADI of 0 - 4 mg/kg bw (expressed as steviol) was established at the 69th JECFA (2008). SYNONYMS INS No. 960 DEFINITION Steviol glycosides consist of a mixture of compounds containing a steviol backbone conjugated to any number or combination of the principal sugar moieties (glucose, rhamnose, xylose, fructose, arabinose, galactose and deoxyglucose) in any of the orientations occurring in the leaves of Stevia rebaudiana Bertoni. The product is obtained from the leaves of Stevia rebaudiana Bertoni. The leaves are extracted with hot water and the aqueous extract is passed through an adsorption resin to trap and concentrate the component steviol glycosides. The resin is washed with a solvent alcohol to release the glycosides and the product is recrystallized from methanol or aqueous ethanol. Ion exchange resins may be used in the purification process. The final product may be spray-dried. Chemical name See Appendix 1 C.A.S. number See Appendix 1 Chemical formula See Appendix 1 Structural formula Steviol (R1 = R2 = H) is the aglycone of the steviol glycosides.
    [Show full text]
  • Rapid and Economic Determination of 13 Steviol Glycosides In
    pubs.acs.org/JAFC Article Rapid and Economic Determination of 13 Steviol Glycosides in Market-Available Food, Dietary Supplements, and Ingredients: Single-Laboratory Validation of an HPLC Method Zhiyan Liu, Kangzi Ren, Ye Feng, Tommy Uong, Scott Krepich, and Hong You* Cite This: https://dx.doi.org/10.1021/acs.jafc.0c03453 Read Online ACCESS Metrics & More Article Recommendations *sı Supporting Information ABSTRACT: Steviol glycosides, obtained from leaves of Stevia rebaudiana Bertoni (stevia) or produced via bioconversion and biosynthesis, are diterpenes used by the food/dietary supplement industry as zero-calorie sweeteners derived from natural sources. JECFA 2017 is the most updated international standardized method but it runs for 80 min per sample with suboptimal separations on several critical pairs for its high-performance liquid chromatography-ultraviolet (HPLC-UV) determination. We developed and validated a rapid and economic HPLC-UV method using the superficially porous particle column to determine 13 steviol glycosides (stevioside, dulcoside A, rubusoside, steviobioside, and rebaudioside A−F, I, M, and N). Baseline separation with a minimum resolution of 1.5 for 13 steviol glycosides was achieved within only 14 min of separation time. The hydrocarbon stationary phase with additional steric interactions from the isobutyl side chains on the C18 ligand was shown to be an important contributor to chromatographic selectivity of several critical pairs of steviol glycosides. The method was proven to perform suitably on columns from three different manufacturers and two HPLC instruments. The method was further used to perform a single-lab validation on eight food and supplement products with multiple matrices. The results ranged from 0.05% w/w rebaudioside A for a hard-candy finished product to 100.8% w/w purity for a rebaudioside M raw ingredient.
    [Show full text]
  • Synthesis and Pharmacological Screening of Novel 1,5
    Vol 2, Issue 1 , 2014 Review Article STEVIOL GLYCOSIDES AND THEIR USE IN FOOD PROCESSING: A REVIEW ROLLY MEHROTRA*1, DHEER SINGH2, AVINASH TIWARI3 1 PhD Student, Centre for Food Technology, Jiwaji University, Gwalior (MP)., 1 Dean, Institute of Engineering and Technology, Bundelkhand University, Jhansi ³ Reader, department of Botany, Jiwaji University, Gwalior (MP) Email: tiwariavinash2@ gmail.com Received: 29 June 2014, Revised and Accepted: 7 August 2014 ABSTRACT Steviol glycosides are the proteinacious secondary metabolites present in the leaves of Stevia rebaudiana Bertoni. These SG’s are the principal sweetening agents which are 200-300 times more sweeter than sucrose. A number of SG’s are present in the leaves of Stevia namely, stevioside, dulcoside A, rebaudioside A, rebaudioside B, rebaudioside C (previously known as dulcoside B), rebaudioside D, rebaudioside E and steviolbioside, 100–125. At the 63rd meeting a temporary ADI of 0-2 mg/kg bodyweight and day, expressed as steviol, was established based on a No-Observed- Effect-Level (NOEL). Steviol glycoside extracts have broad applications as sweetener in the manufacture of fruit and milk drinks, desserts, yoghurt, delicacies, confectioneries, fruit products, processed seafood products, pickles, table-top sweeteners and dietary supplements. Other aspects considered are physicochemical and biologic properties for food processing, stability and therapeutic value of SG’s. nutritional information, Stevia market and household uses. Keywords: Stevia rebaudiana, Steviol glycosides, stevioside and rebaudioside. INTRODUCTION Stevia rebaudiana, a perennial herb from the Asteraceae family, is dulcoside. The two primary compounds, stevioside and rebaudioside known to the scientific world for its sweetness and steviol glycosides A, use only glucose: stevioside has two linked glucose molecules at (SGs).
    [Show full text]
  • Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors
    Neurochemical Research (2019) 44:735–750 https://doi.org/10.1007/s11064-018-02712-1 REVIEW PAPER Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors Sumit Barua1 · Jong Youl Kim1 · Jae Young Kim1 · Jae Hwan Kim4 · Jong Eun Lee1,2,3 Received: 15 October 2018 / Revised: 19 December 2018 / Accepted: 24 December 2018 / Published online: 4 January 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The central nervous system (CNS) is the most injury-prone part of the mammalian body. Any acute or chronic, central or peripheral neurological disorder is related to abnormal biochemical and electrical signals in the brain cells. As a result, ion channels and receptors that are abundant in the nervous system and control the electrical and biochemical environment of the CNS play a vital role in neurological disease. The N-methyl-D-aspartate receptor, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid receptor, kainate receptor, acetylcholine receptor, serotonin receptor, α2-adrenoreceptor, and acid-sensing ion channels are among the major channels and receptors known to be key components of pathophysiological events in the CNS. The primary amine agmatine, a neuromodulator synthesized in the brain by decarboxylation of L-arginine, can regu- late ion channel cascades and receptors that are related to the major CNS disorders. In our previous studies, we established that agmatine was related to the regulation of cell differentiation, nitric oxide synthesis, and murine brain endothelial cell migration, relief of chronic pain, cerebral edema, and apoptotic cell death in experimental CNS disorders.
    [Show full text]
  • Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders Peter A
    University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences 10-19-2010 Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders Peter A. Crooks University of Kentucky, [email protected] Aimee K. Bence David R. Worthen Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Crooks, Peter A.; Bence, Aimee K.; and Worthen, David R., "Agmatine and Agmatine Analogs in the Treatment of Epilepsy, Seizure, and Electroconvulsive Disorders" (2010). Pharmaceutical Sciences Faculty Patents. 47. https://uknowledge.uky.edu/ps_patents/47 This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. US007816407B2 (12) United States Patent (10) Patent N0.: US 7,816,407 B2 Crooks et al. (45) Date of Patent: Oct. 19, 2010 (54) AGMATINE AND AGMATINE ANALOGS IN The Merck Index, Merck Research Laboratories Division of Merck & THE TREATMENT OF EPILEPSY, SEIZURE, Co., Inc. 1996, p. 35. AND ELECTROCONVULSIVE DISORDERS James O. McNamara, “Drugs Effective in Therapy of the Epilepsies”, Goodman & Gilman’s The Pharmacological Basis of Therapeutics, (75) Inventors: Peter A. Crooks, Lexington, KY (US); Ninth Edition, Chapter 20, pp. 461-486, 1996. Aimee K. Bence, Lexington, KY (US); I. Tayfun Uzbay et al., “Effects of agmatine on ethanol Withdrawal David R.
    [Show full text]
  • Figure S1. Heat Map of R (Pearson's Correlation Coefficient)
    Figure S1. Heat map of r (Pearson’s correlation coefficient) value among different samples including replicates. The color represented the r value. Figure S2. Distributions of accumulation profiles of lipids, nucleotides, and vitamins detected by widely-targeted UPLC-MC during four fruit developmental stages. The colors indicate the proportional content of each identified metabolites as determined by the average peak response area with R scale normalization. PS1, 2, 3, and 4 represents fruit samples collected at 27, 84, 125, 165 Days After Anthesis (DAA), respectively. Three independent replicates were performed for each stages. Figure S3. Differential metabolites of PS2 vs PS1 group in flavonoid biosynthesis pathway. Figure S4. Differential metabolites of PS2 vs PS1 group in phenylpropanoid biosynthesis pathway. Figure S5. Differential metabolites of PS3 vs PS2 group in flavonoid biosynthesis pathway. Figure S6. Differential metabolites of PS3 vs PS2 group in phenylpropanoid biosynthesis pathway. Figure S7. Differential metabolites of PS4 vs PS3 group in biosynthesis of phenylpropanoids pathway. Figure S8. Differential metabolites of PS2 vs PS1 group in flavonoid biosynthesis pathway and phenylpropanoid biosynthesis pathway combined with RNA-seq results. Table S1. A total of 462 detected metabolites in this study and their peak response areas along the developmental stages of apple fruit. mix0 mix0 mix0 Index Compounds Class PS1a PS1b PS1c PS2a PS2b PS2c PS3a PS3b PS3c PS4a PS4b PS4c ID 1 2 3 Alcohols and 5.25E 7.57E 5.27E 4.24E 5.20E
    [Show full text]
  • Vitamin D Receptor Promotes Healthy Microbial Metabolites
    www.nature.com/scientificreports OPEN Vitamin D receptor promotes healthy microbial metabolites and microbiome Ishita Chatterjee1, Rong Lu1, Yongguo Zhang1, Jilei Zhang1, Yang Dai 2, Yinglin Xia1 ✉ & Jun Sun 1 ✉ Microbiota derived metabolites act as chemical messengers that elicit a profound impact on host physiology. Vitamin D receptor (VDR) is a key genetic factor for shaping the host microbiome. However, it remains unclear how microbial metabolites are altered in the absence of VDR. We investigated metabolites from mice with tissue-specifc deletion of VDR in intestinal epithelial cells or myeloid cells. Conditional VDR deletion severely changed metabolites specifcally produced from carbohydrate, protein, lipid, and bile acid metabolism. Eighty-four out of 765 biochemicals were signifcantly altered due to the Vdr status, and 530 signifcant changes were due to the high-fat diet intervention. The impact of diet was more prominent due to loss of VDR as indicated by the diferences in metabolites generated from energy expenditure, tri-carboxylic acid cycle, tocopherol, polyamine metabolism, and bile acids. The efect of HFD was more pronounced in female mice after VDR deletion. Interestingly, the expression levels of farnesoid X receptor in liver and intestine were signifcantly increased after intestinal epithelial VDR deletion and were further increased by the high-fat diet. Our study highlights the gender diferences, tissue specifcity, and potential gut-liver-microbiome axis mediated by VDR that might trigger downstream metabolic disorders. Metabolites are the language between microbiome and host1. To understand how host factors modulate the microbiome and consequently alter molecular and physiological processes, we need to understand the metabo- lome — the collection of interacting metabolites from the microbiome and host.
    [Show full text]
  • Identification and Quantification of Major Steviol Glycosides in Stevia
    ARTICLE pubs.acs.org/JAFC Identification and Quantification of Major Steviol Glycosides in Stevia rebaudiana Purified Extracts by 1H NMR Spectroscopy Valerio Pieri,† Andrea Belancic,‡ Susana Morales,‡ and Hermann Stuppner*,† † Institute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Innrain 52c, 6020 Innsbruck, Austria ‡ Prodalysa Ltda, Lote 13, Parque Industrial Gulmue, Camino Internacional, Concon, Chile bS Supporting Information ABSTRACT: The use of 1H NMR spectroscopy for the characterization of Stevia rebaudiana extracts is presented. The developed method allows qualitative and quantitative determination of the major steviol glycosides in purified extracts and fractions obtained from various stages of the purification process. Moreover, it proved to be a powerful tool to differentiate between glycosides which are naturally occurring in the stevia plant and artifacts formed in the course of the manufacturing process. Identification of steviol glycosides was achieved by the use of 2D NMR techniques, whereas quantification is based on qHNMR using anthracene as internal À standard. The solvent mixture pyridine-d5 DMSO-d6 (6:1) enabled satisfactory separation of the signals to be integrated. Validation of the method was performed in terms of specificity, precision, accuracy, linearity, robustness, and stability. Quantitative results were compared to those obtained with the JECFA HPLCÀUV method and were found to be in reasonable agreement. NMR analysis does not rely on the use of reference compounds and enables significantly faster analysis compared to HPLCÀUV. Thus, NMR represents a feasible alternative to HPLC-based methods for the quality control of Stevia rebaudiana extracts. KEYWORDS: Stevia rebaudiana, steviol glycosides, stevioside, rebaudioside A, qHNMR, quality control ’ INTRODUCTION substitutes” must be substantiated as well.
    [Show full text]
  • Steviol Glycoside Determination by HPLC with Charged Aerosol and UV Detections Using the Acclaim Trinity P1 Column
    Application Note: 293 Steviol Glycoside Determination by HPLC with Charged Aerosol and UV Detections Using the Acclaim Trinity P1 Column Deanna Hurum and Jeffrey Rohrer; Sunnyvale, CA USA Introduction Steviol glycoside determination is challenging for Key Words In December 2008, the U.S. FDA recognized rebaudioside multiple reasons. The structures of the steviol glycosides are quite similar, differing in small changes in glycosylation. For • Stevia A purified from Stevia rebaudiana (Bertoni) as Generally Recognized as Safe (GRAS) for use as a sugar substitute example, rebaudioside B, an impurity that can be formed • Rebaudioside A in foods.1,2 Since this recognition, stevia products have during processing of the leaves, differs in structure from rebaudioside A primarily by the presence or absence of a • HILIC become popular as table-top and beverage sweeteners. Although the stevia plant and extracts from stevia leaves glucose residue at the R1 position on the terpene (Figure 2). These • Natural have long been used as sweeteners in Asia and Latin structural similarities make chromatographic separation Sweeteners America, the terpene glycosides have different flavor difficult. In addition to the separation challenges, sensitive profiles with both sweet and unpleasant bitter flavors.3 detection of these compounds also can be difficult. They Two steviol glycosides, stevioside and rebaudioside A, are do not absorb strongly in the UV, and typical detection largely responsible for the desired sweet flavor of the leaves wavelengths for steviol glycosides, such as 210 nm, are (Figure 1), with rebaudioside A preferred for sweeteners.4 nonspecific. Other detection methods, such as charged aerosol, can be used in addition to UV detection to improve steviol glycoside quantification.
    [Show full text]
  • Uncovering New Drug Properties in Target-Based Drug-Drug Similarity Networks
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.12.988600; this version posted June 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Uncovering new drug properties in target-based drug-drug similarity networks Lucret¸iaUdrescu1, Paul Bogdan2, Aimee´ Chis¸ 3, Ioan Ovidiu Sˆırbu3,6, Alexandru Topˆırceanu4, Renata-Maria Varut¸˘ 5, and Mihai Udrescu4,6,* 1”Victor Babes¸” University of Medicine and Pharmacy Timis¸oara, Department of Drug Analysis, Timis¸oara 300041, Romania 2University of Southern California, Ming Hsieh Department of Electrical Engineering, Los Angeles, CA 90089-2563, USA 3”Victor Babes¸” University of Medicine and Pharmacy Timis¸oara, Department of Biochemistry, Timis¸oara 300041, Romania 4University Politehnica of Timis¸oara, Department of Computer and Information Technology, Timis¸oara 300223, Romania 5University of Medicine and Pharmacy of Craiova, Faculty of Pharmacy, Craiova 200349, Romania 6Timis¸oara Institute of Complex Systems, Timis¸oara 300044, Romania *[email protected] ABSTRACT Despite recent advances in bioinformatics, systems biology, and machine learning, the accurate prediction of drug properties remains an open problem. Indeed, because the biological environment is a complex system, the traditional approach – based on knowledge about the chemical structures – cannot fully explain the nature of interactions between drugs and biological targets. Consequently, in this paper, we propose an unsupervised machine learning approach that uses the information we know about drug-target interactions to infer drug properties.
    [Show full text]